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1. 
MICROBAL STRANS AND METHODS OF 
MAKING AND USING 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit under 35 U.S.C. S 119(e) to 
U.S. Application No. 61/980,656, filed on Apr. 17, 2014. 
FEDERALLY SPONSORED RESEARCH OR 
DEVELOPMENT 
This invention was made with government Support under 
RR017675 awarded by the National Institutes of Health. The 
government has certain rights in the invention. 
TECHNICAL FIELD 
This disclosure generally relates to microbial strains and 
methods of making and using. 
BACKGROUND 
Methane is an increasingly important global energy 
Source, both as the primary component of natural gas and as 
a biologically produced fuel. Currently, Sweden uses 100% 
renewable methane (biogas) in place of compressed natural 
gas (CNG) for transportation fuel, and several European 
countries are implementing policies to increase their pro 
portion of biogas transportation fuel. In addition, methane is 
a valuable chemical for conversion into other higher-order 
carbon compounds (e.g., methanol, formate, alkanes, ter 
penes). More than 50% of the world's methane is produced 
biologically by anaerobic archaea called methanogens, but 
one significant limitation with industrial scale biological 
methane production from any type of feedstock is that the 
rate is relatively slow. 
Methanosarcina acetivorans is one of a unique group of 
organisms capable of producing methane from both acetate 
and methylated compounds, which are common anaerobic 
fermentation end products. A genetically engineered M. 
acetivorans strain is described herein that exhibits an 
increased rate of methane production on methanol and on 
acetate. Such genetically engineered microorganisms will be 
an essential tool in the ability to use methanogens as an 
inexpensive source of methane fuel derived from renewable 
biomass. 
SUMMARY 
The disclosure provides microbial strains and methods of 
making and using Such microbial strains. 
In one aspect, a HarABC nucleic acid molecule including 
a mutation is provided. In some embodiments, the non 
mutant HarABC sequence is shown in SEQ ID NO:1. In 
Some embodiments, the mutation is selected from the group 
consisting of a point mutation, an insertion, a deletion, and 
a substitution. In some embodiments, the mutant HodrABC 
sequence is shown in SEQID NO:5. In some embodiments, 
the nucleic acid encodes a polypeptide having an amino acid 
sequence shown in SEQ ID NO:6. In some embodiments, 
the mutation is at position 249 relative to SEQID NO:6. In 
some embodiments, the mutation is a M249V substitution. 
In another aspect, a microorganism including Such a 
nucleic acid molecule is provided. Such a microorganism 
can be a methanogen. In one embodiments, the microorgan 













the nucleic acid molecule is endogenous to the microorgan 
ism. In some embodiments, the nucleic acid molecule is 
exogenous to the microorganism and is expressed via a 
COnStruct. 
In yet another aspect, a mutant HodrB polypeptide is 
provided. In some embodiments, the mutation includes a 
substitution at position 249 relative to SEQ ID NO:3. In 
Some embodiments, the mutation includes a Substitution of 
the methionine at position 249 relative to SEQID NO:3. In 
Some embodiments, the Substitution is a conservative Sub 
stitution. In some embodiments, the mutant HarB polypep 
tide has the sequence shown in SEQ ID NO:6. 
In still another aspect, a microorganism that includes a 
mutant HodrB polypeptide is provided. Such a microorgan 
ism can be a methanogen. In some embodiments, the micro 
organism is Methanosarcina acetivorans. In some embodi 
ments, the nucleic acid encoding the polypeptide is 
endogenous to the microorganism. In some embodiments, 
the nucleic acid encoding the polypeptide is exogenous to 
the microorganism and is expressed via a construct. 
In another aspect, a method of producing methane is 
provided. Such a method typically includes culturing a 
microorganism as described herein under appropriate con 
ditions. 
In still another aspect, a method of biogas production is 
provided. Such a method typically includes culturing a 
microorganism as described herein under appropriate con 
ditions. 
Unless otherwise defined, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
methods and compositions of matter belong. Although meth 
ods and materials similar or equivalent to those described 
herein can be used in the practice or testing of the methods 
and compositions of matter, Suitable methods and materials 
are described below. In addition, the materials, methods, and 
examples are illustrative only and not intended to be limit 
ing. All publications, patent applications, patents, and other 
references mentioned herein are incorporated by reference in 
their entirety. 
DESCRIPTION OF DRAWINGS 
FIG. 1 shows the method of construction of plasmid pC1 
and strain verification. Panel A shows the map of plasmid 
pC1 containing the M. acetivorans hdraBC operon under 
control of the P(tet) promoter. Panel B shows an agarose gel 
indicating PCR identification of each strain. Asterisks 
denote the location of point mutations in the hdraBC 
operon. 
FIG. 2 shows the genomic organization of each strain, 
including the hadr A1C1 B1 locus in the parent strain and the 
AhdraBC mutant strain before and after integration of 
plasmid pC1. Blue arrows show primer binding sites. 
Asterisks denote the location of point mutations in the 
hdraBC operon. 
FIG. 3 are graphs showing the growth curves of Strains 
grown in 96-well plates on methanol--acetate medium (panel 
A), and in sealed vessels on methanol medium (panel B). 
Parental strain (black circles), AhdraBC mutant (gray tri 
angles), plasmid pC1 integrated in the AhdraBC deletion 
mutant (AhdraBC att::hdraBC, blue diamonds), plasmid 
pC1 integrated into the parent strain (atthdraBC, red 
squares). Growth data was collected from triplicate biologi 
cal replicates. 
FIG. 4 are graphs showing the phenotypes of parent and 
hdraBC mutant strains. Rates of methane production by cell 
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Suspensions were measured from cells grown on methanol 
(panel A) and acetate (panel B). Methane production was 
measured in triplicate biological and triplicate technical 
replicates. Asterisks indicate p-0.0001. Panel C shows het 
erodisulfide reductase activity in methanol-grown cell 
extracts. Assays were performed in triplicate. Error bars 
denote the standard deviation. 
FIG. 5 shows the correlative relationships between 
HdrABC expression level and methane rate, growth rate, 
and total biomass synthesis. Panel A shows that the rate of 
methane production is directly dependent on the amount of 
HdrABC enzyme activity in the cell (R* correlation coeffi 
cient of 1.00). Panel B shows the second-order relationship 
between growth rate and methane production rate (R cor 
relation coefficient of 0.981). Panel C shows the second 
order relationship between growth rate and HarABC 
enzyme activity (R correlation coefficient of 0.990). Panel 
D shows HarABC enzyme activity has a strong negative 
correlation with total biomass synthesis (R correlation 
coefficient of 0.959). Error bars denote the standard devia 
tion. 
FIG. 6 shows the mechanism of methane rate improve 
ment in the hdraBC overexpressing strain. Panel A shows 
the metabolic efficiency of each strain. Values are normal 
ized to the AhdraBC mutant strain. Panel B shows a strong 
negative correlation between HarABC enzyme activity and 
metabolic efficiency (R-0.961). Error bars denote the stan 
dard deviation. 
DETAILED DESCRIPTION 
A microbial strain is described herein, designated NB105, 
which produces methane at a significantly faster rate than 
the wild type strain (FIG. 1). The NB105 strain described 
herein also grows faster than the parent strain under certain 
conditions. This microbial strain represents a transformative 
contribution to the field of renewable methane and the 
production of biogas. 
Attempts have been made for about thirty years to 
increase biogas yield but, to date, no method has been 
commercially Successful. One problem is that the strains 
used in commercial-scale production facilities are not 
genetically tractable and the strains that have proven to be 
genetically tractable are, in other ways, not suitable for 
commercial scale production digesters. In addition, there are 
only a few laboratories around the world that have been able 
to genetically manipulate the anaerobic microbes involved. 
Simply by way of example, efficient genetic modification of 
strict anaerobic microbes requires specialized microbiology, 
genetics, as well as custom-built equipment. In addition, 
genetic modification of Methanosarcinales and Methanococ 
cus methanogens must be performed in high osmolarity 
medium (e.g., containing 0.4 M Sodium chloride), which is 
not routine. Further, the lack of commercially available 
co-enzymes and co-factors for anaerobes (such as co-en 
Zyme B, co-enzyme F430, co-enzyme F420), means that the 
cofactors must be extracted or synthesized. Therefore, 
genetic investigation of biosynthetic pathways in anaerobes 
is prohibitively difficult. Methanogens also are not suscep 
tible to most traditional antibiotics, so the paucity of select 
able and counterselectable markers for genetically manipu 
lating methanogens adds another layer of complexity that 
serves as a significant barrier to working with methanogens. 
The microbial strains described herein have been 
designed using a specialized knowledge of the biology, 
genetics, and biochemistry of microbial fermentation, 














carbon feedstocks. The microbial strains described herein 
demonstrate that it is, in fact, possible to genetically engi 
neer an increase in the rate and yield of biogas production in 
methanogens. 
The HarABC Operon 
Methanogenic archaea have been divided into two cat 
egories: those that contain cytochromes and can use metha 
nol, methyl amines, acetate, carbon monoxide, and/or CO 
plus H2 as methanogenic Substrates (i.e., those belonging to 
the order Methanosarcinales), and those that are devoid of 
cytochromes and can use CO plus H2 and/or formate only 
to fuel anaerobic growth (i.e., those belonging to the orders 
Methanobacteriales, Methanomicrobiales, Methanococca 
les, and Methanopyrales). See, for example, Thauer, 1998, 
Microbiol., 144:2377-406; and Wolfe, 1996, ASM News, 
62:529-34. 
In methanogens that lack cytochromes, the heterodisulfide 
reductase-like proteins (HDR) enzyme is soluble and com 
posed of three subunits, HdrABC, whereas methanogens 
that have cytochromes have two classes of HDR enzyme: 
HdrABC, as in non-cytochrome containing methanogens, as 
well as membrane-associated HDR formed by two subunits, 
HdrDE. In the HarABC enzyme, the HarA subunit is an 
iron-sulfur flavoprotein, the HarC subunit is a small iron 
sulfur protein, and the HarB subunit contains two GGC 
domains and harbors a special 4Fe4S catalytic site. 
The soluble HarABC enzyme forms a complex with the 
soluble MvhaDGHase, which then catalyzes heterodisulfide 
reduction in the presence of H2. This exergonic reaction is 
proposed to be coupled to the endergonic reduction of 
ferredoxin (Fd) by flavin-based electron bifurcation involv 
ing HarA (see, for example, Thauer et al., 2008, Nat. Rev. 
Microbiol. 6:579-91). Flavin-based electron bifurcation 
(FBEB) is an important mechanism for the energy metabo 
lism of anaerobes. A family of NADH dehydrogenases, the 
flavin oxidoreductase (Flx ABCD, previously called Flox 
ABCD), coupled with heterodisulfide reductase (HdrABC), 
both of which are widespread in anaerobic bacteria, perform 
FBEB in Sulphate-reducing organisms. 
HdrABC Nucleic Acids and Polypeptides 
The nucleic acid sequence of a reference wild type 
HdrABC operon is shown in SEQID NO:1 with each of the 
encoded reference polypeptides shown in SEQ ID NO:2 
(HdrA), SEQ ID NO:3 (HdrB), and SEQID NO:4 (HdrC)). 
As used herein, nucleic acids can include DNA and RNA, 
and includes nucleic acids that contain one or more nucleo 
tide analogs or backbone modifications. A nucleic acid can 
be single stranded or double stranded, which usually 
depends upon its intended use. 
Also provided are nucleic acids and polypeptides that 
differ from such reference sequences (e.g., SEQ ID NO:1 
and SEQ ID NOS: 2, 3 and 4, respectively). Nucleic acids 
and polypeptides that differ in sequence from SEQID NO:1 
and SEQID NOS: 2, 3, or 4, can have at least 50% sequence 
identity (e.g., at least 55%, 60%. 65%, 70%, 75%, 80%, 
81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% 
sequence identity) to SEQ ID NO:1 and SEQID NOs: 2, 3, 
or 4, respectively. Simply by way of example, sequences that 
differ from SEQ ID NO:1 and SEQ ID NO:3 are shown in 
SEQ ID NO:5 and SEQ ID NO:6, respectively. 
In calculating percent sequence identity, two sequences 
are aligned and the number of identical matches of nucleo 
tides or amino acid residues between the two sequences is 
determined. The number of identical matches is divided by 
the length of the aligned region (i.e., the number of aligned 
nucleotides or amino acid residues) and multiplied by 100 to 
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arrive at a percent sequence identity value. It will be 
appreciated that the length of the aligned region can be a 
portion of one or both sequences up to the full-length size of 
the shortest sequence. It also will be appreciated that a single 
sequence can align with more than one other sequence and 
hence, can have different percent sequence identity values 
over each aligned region. 
The alignment of two or more sequences to determine 
percent sequence identity can be performed using the com 
puter program ClustalW and default parameters, which 
allows alignments of nucleic acid or polypeptide sequences 
to be carried out across their entire length (global align 
ment). Chenna et al., 2003, Nucleic Acids Res., 31 (13): 
3497-500. ClustalW calculates the best match between a 
query and one or more subject sequences, and aligns them 
so that identities, similarities and differences can be deter 
mined. Gaps of one or more residues can be inserted into a 
query sequence, a Subject sequence, or both, to maximize 
sequence alignments. For fast pairwise alignment of nucleic 
acid sequences, the default parameters can be used (i.e., 
word size: 2; window size: 4; scoring method: percentage; 
number of top diagonals: 4; and gap penalty: 5); for an 
alignment of multiple nucleic acid sequences, the following 
parameters can be used: gap opening penalty: 10.0; gap 
extension penalty: 5.0, and weight transitions: yes. For fast 
pairwise alignment of polypeptide sequences, the following 
parameters can be used: word size: 1; window size: 5; 
scoring method: percentage; number oftop diagonals: 5; and 
gap penalty: 3. For multiple alignment of polypeptide 
sequences, the following parameters can be used: weight 
matrix: blosum, gap opening penalty: 10.0; gap extension 
penalty: 0.05; hydrophilic gaps: on; hydrophilic residues: 
Gly, Pro, Ser, ASn, Asp, Gln, Glu, Arg, and Lys; and 
residue-specific gap penalties: on. ClustalW can be run, for 
example, at the Baylor College of Medicine Search 
Launcher website or at the European Bioinformatics Insti 
tute website on the World Wide Web. 
Changes can be introduced into a nucleic acid molecule, 
thereby leading to changes in the amino acid sequence of the 
encoded polypeptide. For example, changes can be intro 
duced into nucleic acid coding sequences using mutagenesis 
(e.g., site-directed mutagenesis, PCR-mediated mutagen 
esis) or by chemically synthesizing a nucleic acid molecule 
having Such changes. Such nucleic acid changes can lead to 
conservative and/or non-conservative amino acid substitu 
tions at one or more amino acid residues. A "conservative 
amino acid substitution' is one in which one amino acid 
residue is replaced with a different amino acid residue 
having a similar side chain (see, for example, Dayhoff et al. 
(1978, in Atlas of Protein Sequence and Structure, 5(Suppl. 
3):345-352), which provides frequency tables for amino acid 
Substitutions), and a non-conservative Substitution is one in 
which an amino acid residue is replaced with an amino acid 
residue that does not have a similar side chain. 
As used herein, a mutant HodrABC nucleic acid refers to 
an HodrABC operon that contains at least one mutation. A 
mutation can be located within any portion of the HarABC 
nucleic acid operon Such that any of the encoded polypep 
tides, HdrA, HdrB or HodrC, contain a mutation. As used 
herein, a mutation within HarABC typically is a mutation 
that results in, for example, a conservative or non-conser 
vative substitution; a mutation within HarABC typically is 
not a null mutation (i.e., a mutation that results in the lack 
of expression or in a non-functional protein). A mutation in 
a HarABC sequence as described herein can be contained 
within an endogenous HodrABC sequence or a mutation in a 













within an exogenous sequence (e.g., expressed/overex 
pressed on a construct). In addition, a mutant HarABC 
sequence can be autologous (i.e., from the same species) or 
heterologous (i.e., from a different species) to a microor 
ganism. 
A representative HarABC nucleic acid containing a muta 
tion is shown in SEQ ID NO:5, and a representative HarB 
protein that contains a mutation is shown in SEQID NO:6. 
In some embodiments, the mutation can at position 249 
relative to the HarB sequence shown in SEQ ID NO:3 and, 
for the reference sequence shown in SEQ ID NO:3, the 
mutation corresponds to a methionine to valine Substitution 
(i.e., M249V). As indicated herein, however, other substi 
tutions at that residue (e.g., residue 249 relative to SEQ ID 
NO:3) also would be expected to impart the same or similar 
phenotype (e.g., M249X). In some instances, the methionine 
residue at position 249 can be replaced, for example, with an 
alanine (M249A), an isoleucine (M249I), a leucine 
(M249L), or a glycine (M249G) residue. Alternatively, the 
methionine residue at position 249 can be replaced, for 
example, with a phenylalanine (M249F), a proline (M249P), 
a tryrosine (M249Y), or a tryptophan (M249W). It would be 
understood by a skilled artisan that the methionine residue at 
position 249 can be replaced with any of the other remaining 
amino acids, provided Such Substitutions do not result in a 
protein that completely lacks function and provided Such 
Substitutions impart the desired phenotype. 
As used herein, an "isolated nucleic acid molecule is a 
nucleic acid molecule that is free of sequences that naturally 
flank one or both ends of the nucleic acid in the genome of 
the organism from which the isolated nucleic acid molecule 
is derived (e.g., a cDNA or genomic DNA fragment pro 
duced by PCR or restriction endonuclease digestion). Such 
an isolated nucleic acid molecule is generally introduced 
into a vector (e.g., a cloning vector, or an expression vector) 
for convenience of manipulation or to generate a fusion 
nucleic acid molecule, discussed in more detail below. In 
addition, an isolated nucleic acid molecule can include an 
engineered nucleic acid molecule Such as a recombinant or 
a synthetic nucleic acid molecule. 
As used herein, a “purified’ polypeptide is a polypeptide 
that has been separated or purified from cellular components 
that naturally accompany it. Typically, the polypeptide is 
considered “purified when it is at least 70% (e.g., at least 
75%, 80%, 85%, 90%. 95%, or 99%) by dry weight, free 
from the polypeptides and naturally occurring molecules 
with which it is naturally associated. Since a polypeptide 
that is chemically synthesized is, by nature, separated from 
the components that naturally accompany it, a synthetic 
polypeptide is “purified.” 
Nucleic acids can be isolated using techniques routine in 
the art. For example, nucleic acids can be isolated using any 
method including, without limitation, recombinant nucleic 
acid technology, and/or the polymerase chain reaction 
(PCR). General PCR techniques are described, for example 
in PCR Primer: A Laboratory Manual, Dieffenbach & Dvek 
sler, Eds. Cold Spring Harbor Laboratory Press, 1995. 
Recombinant nucleic acid techniques include, for example, 
restriction enzyme digestion and ligation, which can be used 
to isolate a nucleic acid. Isolated nucleic acids also can be 
chemically synthesized, either as a single nucleic acid mol 
ecule or as a series of oligonucleotides. 
Polypeptides can be purified from natural Sources (e.g., a 
biological sample) by known methods such as DEAE ion 
exchange, gel filtration, and hydroxyapatite chromatogra 
phy. A polypeptide also can be purified, for example, by 
expressing a nucleic acid in an expression vector. In addi 
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tion, a purified polypeptide can be obtained by chemical 
synthesis. The extent of purity of a polypeptide can be 
measured using any appropriate method, e.g., column chro 
matography, polyacrylamide gel electrophoresis, or HPLC 
analysis. 
A construct, also referred to as a vector, containing a 
nucleic acid (e.g., a nucleic acid that encodes a polypeptide) 
also is provided. Constructs, including expression vectors, 
are commercially available or can be produced by recom 
binant DNA techniques routine in the art. A construct 
containing a nucleic acid can have expression elements 
operably linked to such a nucleic acid, and further can 
include sequences such as those encoding a selectable 
marker (e.g., an antibiotic resistance gene). A construct 
containing a nucleic acid can encode a chimeric or fusion 
polypeptide (i.e., a polypeptide operatively linked to a 
heterologous polypeptide, which can be at either the N-ter 
minus or C-terminus of the polypeptide). Representative 
heterologous polypeptides are those that can be used in 
purification of the encoded polypeptide (e.g., 6x His tag, 
glutathione S-transferase (GST)) 
Expression elements include nucleic acid sequences that 
direct and regulate expression of nucleic acid coding 
sequences. One example of an expression element is a 
promoter sequence. Expression elements also can include 
introns, enhancer sequences, response elements, or inducible 
elements that modulate expression of a nucleic acid. Expres 
sion elements can be of bacterial, yeast, insect, mammalian, 
or viral origin, and vectors can contain a combination of 
elements from different origins. As used herein, operably 
linked means that a promoter or other expression element(s) 
are positioned in a construct relative to a nucleic acid in such 
a way as to direct or regulate expression of the nucleic acid 
(e.g., in-frame). 
A skilled artisan would appreciate that gene expression in 
methanogens typically requires at least one methanogen 
specific expression element, since the transcriptional 
machinery in methanogens is a hybrid between bacterial and 
eukaryotic transcription systems. For example, for expres 
sion of genes in methanogens, the promoter is usually 
derived from another methanogen gene to ensure that the 
methanogen RNA polymerase and other accessory proteins 
needed for transcription will recognize the promoter 
sequences and initiate transcription. However, other expres 
sion elements such as protein transcriptional regulators 
and/or riboswitches from phylogenetically distant relatives 
(e.g., eukaryotic or bacterial) can be adapted for use in 
methanogen cells. See, for example, Buan et al., 2011, 
Methods Enzymol., 494:23-42; Demolli et al., 2014, Archea, 
do: 10.1155/2014/72561O. 
Constructs as described herein can be introduced into a 
host cell. As used herein, “host cell refers to the particular 
cell into which the nucleic acid is introduced and also 
includes the progeny of Such a cell that carry the construct. 
A host cell can be any prokaryotic or eukaryotic cell. For 
example, nucleic acids can be expressed in bacterial cells 
Such as E. coli, or in insect cells, yeast or mammalian cells 
(such as Chinese hamster ovary cells (CHO) or COS cells). 
Other suitable host cells are known to those skilled in the art. 
Many methods for introducing nucleic acids into host cells, 
both in vivo and in vitro, are well known to those skilled in 
the art and include, without limitation, electroporation, 
calcium phosphate precipitation, polyethylene glycol (PEG) 
transformation, heat shock, lipofection, microinjection, and 
viral-mediated nucleic acid transfer. 
Nucleic acids can be detected using any number of 













tory Manual, 1995, Dieffenbach & Dveksler, Eds. Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.: 
and U.S. Pat. Nos. 4,683, 195; 4,683.202; 4,800,159; and 
4.965, 188) with an appropriate pair of oligonucleotides 
(e.g., primers). A number of modifications to the original 
PCR have been developed and can be used to detect a 
nucleic acid. 
Nucleic acids also can be detected using hybridization. 
Hybridization between nucleic acids is discussed in detail in 
Sambrook et al. (1989, Molecular Cloning: A Laboratory 
Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, 
Cold Spring Harbor, N.Y.; Sections 7.37-7.57, 9.47-9.57, 
11.7-11.8, and 11.45-11.57). Sambrook et al. discloses suit 
able Southern blot conditions for oligonucleotide probes less 
than about 100 nucleotides (Sections 11.45-11.46). The Tm 
between a sequence that is less than 100 nucleotides in 
length and a second sequence can be calculated using the 
formula provided in Section 11.46. Sambrook et al. addi 
tionally discloses Southern blot conditions for oligonucle 
otide probes greater than about 100 nucleotides (see Sec 
tions 9.47-9.54). The Tm between a sequence greater than 
100 nucleotides in length and a second sequence can be 
calculated using the formula provided in Sections 9.50-9.51 
of Sambrook et al. 
The conditions under which membranes containing 
nucleic acids are prehybridized and hybridized, as well as 
the conditions under which membranes containing nucleic 
acids are washed to remove excess and non-specifically 
bound probe, can play a significant role in the stringency of 
the hybridization. Such hybridizations and washes can be 
performed, where appropriate, under moderate or high Strin 
gency conditions. For example, washing conditions can be 
made more stringent by decreasing the salt concentration in 
the wash solutions and/or by increasing the temperature at 
which the washes are performed. Simply by way of 
example, high Stringency conditions typically include a 
wash of the membranes in 0.2XSSC at 65° C. 
In addition, interpreting the amount of hybridization can 
be affected, for example, by the specific activity of the 
labeled oligonucleotide probe, by the number of probe 
binding sites on the template nucleic acid to which the probe 
has hybridized, and by the amount of exposure of an 
autoradiograph or other detection medium. It will be readily 
appreciated by those of ordinary skill in the art that although 
any number of hybridization and washing conditions can be 
used to examine hybridization of a probe nucleic acid 
molecule to immobilized target nucleic acids, it is more 
important to examine hybridization of a probe to target 
nucleic acids under identical hybridization, washing, and 
exposure conditions. Preferably, the target nucleic acids are 
on the same membrane. 
A nucleic acid molecule is deemed to hybridize to a 
nucleic acid but not to another nucleic acid if hybridization 
to a nucleic acid is at least 5-fold (e.g., at least 6-fold, 7-fold, 
8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-fold) greater 
than hybridization to another nucleic acid. The amount of 
hybridization can be quantitated directly on a membrane or 
from an autoradiograph using, for example, a Phosphorm 
ager or a Densitometer (Molecular Dynamics, Sunnyvale, 
Calif.). 
Polypeptides can be detected using antibodies. Tech 
niques for detecting polypeptides using antibodies include 
enzyme linked immunosorbent assays (ELISAs), Western 
blots, immunoprecipitations and immunofluorescence. An 
antibody can be polyclonal or monoclonal. An antibody 
having specific binding affinity for a polypeptide can be 
generated using methods well known in the art. The anti 
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body can be attached to a solid Support such as a microtiter 
plate using methods known in the art. In the presence of a 
polypeptide, an antibody-polypeptide complex is formed. 
Detection (e.g., of an amplification product, a hybridiza 
tion complex, or a polypeptide) is usually accomplished 
using detectable labels. The term “label' is intended to 
encompass the use of direct labels as well as indirect labels. 
Detectable labels include enzymes, prosthetic groups, fluo 
rescent materials, luminescent materials, bioluminescent 
materials, and radioactive materials. 
Methods of Making Biogas 
The microbial strains described herein can be used to 
make biogas (e.g., methane). As demonstrated herein, cul 
turing such microbial strains under the appropriate condi 
tions results in the production of biogas (e.g., methane). It 
would be appreciated by a skilled artisan that the “appro 
priate conditions’ under which a microorganism is cultured 
will depend upon the particular microorganism used, and 
can include, without limitation, a particular culture media, 
the temperature at which the culture is maintained, the 
requirement for the presence or absence of oxygen, a par 
ticular carbon Source, and/or one or more co-factors. 
The microbial strains described herein can be used to 
make biogas (e.g., methane) at an increased rate relative to 
the parent strain and/or an increased amount relative to the 
parent strain. For example, as described herein, under cor 
responding culture conditions, the parent strain, NB34. 
produced methane at a rate of 219+18.9 nmoles min-1 mg-1. 
while one of the mutant strains described herein, NB105 
(att::hdraBC), produced methane at a rate of 282+31.8 
nmoles min-1 mg-1; this represents a 28.9% increase in rate. 
As used herein, an “increase' in the amount of biogas that 
is produced or an increase in the rate at which a biogas is 
produced refers to an increase (e.g., a statistically significant 
increase) by at least about 5% up to about 95% (e.g., about 
5% to about 10%, about 5% to about 20%, about 5% to about 
50%, about 5% to about 75%, about 10% to about 25%, 
about 10% to about 50%, about 10% to about 90%, about 
20% to about 40%, about 20% to about 60%, about 20% to 
about 80%, about 25% to about 75%, about 35% to about 
55%, about 35% to about 50%, about 50% to about 75%, 
about 50% to about 85%, about 50% to about 95%, and 
about 75% to about 95%) relative to a corresponding 
microbe lacking the mutation. It would be appreciated by a 
person of ordinary skill in the art that, to compare a mutant 
microbial Strain with a corresponding microbial strain lack 
ing the mutation, culture conditions used to grow each 
microbial strain should be as similar as possible, referred to 
herein as “corresponding conditions'. As used herein, sta 
tistical significance refers to a p-value of less than 0.05, e.g., 
a p-value of less than 0.025 or a p-value of less than 0.01, 
using an appropriate measure of Statistical significance, e.g., 
a one-tailed two sample t-test. 
Current practices for producing renewable methane use 
innocula of microbes, usually obtained from animal manure 
(e.g., Swine or cattle manure) to digest organic carbon under 
anaerobic conditions. As a result, anaerobic digesters fre 
quently fail and must be shut down, cleaned, and restarted on 
a regular basis. These failures represent a large cost in time, 
effort, wages, and lost revenue. The methods described 
herein can be used to increase biogas yield, require less 
feedstock, increase the overall rate of feedstock decompo 
sition, reduce labor, and help stabilize production because 
operators would not solely rely on populations of wild 
microbes as the feedstock. In addition, the methods 
described herein require less feedstock than current meth 













plant downtime and labor costs. Thus, the methods 
described herein can significantly reduce the costs involved 
with the production of biogas. 
In some embodiments, a live culture of the microbial 
strain described herein is added (e.g., inoculated) to a 
digester at regular intervals. In some embodiments, the 
microbial strains described herein can be provided in, for 
example, a lyophilized or dehydrated form. One of the 
advantages of the microbial strain described herein is that, 
because it is anaerobic, in the absence of very particular 
growth conditions, microbes from the microbial strain 
described herein will not survive. This feature significantly 
reduces the possibility of unintentional release into the 
environment. 
Additional mutations can be introduced into the microbial 
strain described herein to further increase biogas production 
or to increase other features of the Strain Such as, for 
example, yield, increased growth rate, the ability to use 
novel Substrates, or resistance to oxidative stress. The micro 
bial strain described herein also can be a part of a microbial 
consortia (e.g., a microbial community that has evolved 
together) to be able to efficiently convert various renewable 
feedstocks to methane and/or additional fermentation co 
products. 
Biogas made by the methods described herein can be 
used, without limitation, for renewable energy, compressed 
biogas/natural gas for transportation, microbial fermentation 
or respiration (bioorganic catalysis), or any other technology 
that uses methane or biogas including (in)organic catalytic 
synthesis technologies. 
Further, a mutant HarABC nucleic acid sequence as 
described herein can be introduced into other microbial 
organisms having industrial or biotechnological utility in 
order to alter those strains. HarABC homologs and 
orthologs are found in the genomes of non-methanogenic 
archaea and bacteria, Such as members of the genus Metal 
losphaera, Archaeoglobus, Sulfate-reducing bacteria (in 
cluding, but not restricted to, Desulfovibrio, Desulfotomacu 
lum), Moorella, Aquifex, Sulfolobus, Carboxydothermus, 
Pelotomaculum, Chlorflexi (including, but not restricted to, 
Chloroflexus, Chlorobium), syntrophs (including, but not 
restricted to, Syntrophomonas), and metal-reducing or 
metal-oxidizing microbes such as Geobacter, and could be 
mutated (or a mutant sequence overexpressed) in any of 
Such species The above-mentioned mutant species can be 
used for bioremediation or metal bioleaching, aerobic or 
anaerobic fermentations (including gas fermentation), and 
production of biofuel cells, and would exhibit increased rate 
and yield of fermentation and/or respiration. 
In accordance with the present invention, there may be 
employed conventional molecular biology, microbiology, 
biochemical, and recombinant DNA techniques within the 
skill of the art. Such techniques are explained fully in the 
literature. The invention will be further described in the 
following examples, which do not limit the scope of the 
methods and compositions of matter described in the claims. 
EXAMPLES 
Example 1 
Materials and Methods 
Cell growth curves were determined by monitoring the 
optical density (OD) of the cells in culture over time. The 
OD of the cells was determined using two methods as 
indicated: (1) using growth in Balch tubes and obtaining the 
US 9,598,678 B2 
11 
OD manually every 4 hours for 3-7 days using a Spectronic 
20 D+ spectrophotomter (“BT+Spec 20), where; or (2) 
using an anaerobic plate reader and obtaining the OD 
automatically every 2 hours. For biomass measurements of 
each strain, ten cultures (10 ml) were grown to stationary 
phase on HS medium containing 125 mM MeOH. Methane 
in the headspace was measured as described below, and cells 
were collected on pre-weighed 0.2 um nylon filters by 
vacuum. Filters were dried at 95°C. and weighed daily until 
weights stabilized and remained consistent for three days. 
Uninoculated medium was used as a blank. 
The amount and rate of methane production was deter 
mined using gas chromatography (GC). For methane end 
point assays, 10 ml cultures were grown in 125 mM metha 
nol HS medium to stationary phase, and 100 ul headspace 
samples were transferred to empty, crimped 2 ml serum vials 
using a gastight Hamilton Syringe. For cell Suspension 
assays, cells were grown with appropriate carbon source to 
an OD(600) of between 0.3 and 0.5 (exponential growth) 
and put on ice. Under strict anaerobic conditions, cells from 
10 ml culture were harvested, pelleted by centrifugation, and 
washed twice in HS media without a carbon source. Cells 
were resuspended in 0.5 ml HS media with 50 uM mupirocin 
to halt protein synthesis, then aliquoted into 2 ml serum vials 
containing HS+125 mM MeOH or 120 mM acetate in 
replicates of 5. Serum vials were sealed with aluminum 
crimps and warmed for 5 minutes at 35°C. to start the assay. 
Methane in the headspace was measured via flame ioniza 
tion on an Agilent 7890 Gas Chromatograph with a GS 
CarbonPLOT column at 145° C. using an auto injector. 
The amount of HarABC enzyme activity was measured 
by biochemical assay. Coenzyme M was purchased from 
Sigma-Aldrich (St. Louis, Mo.). Coenzyme B and CoM-S- 
S-CoB was synthesized in-house (Welte and Deppenmeier, 
2014, Biochim. Biophys. Acta., 1837: 1130-47). Cells were 
grown to early stationary phase (OD(600) of 1.0) in HS 
supplemented with 125 mM MeCH. Under strict anaerobic 
conditions, 30 ml of cell cultures were harvested, pelleted by 
centrifugation, and washed twice with 10 ml 0.1 M NaPO, 
0.4 M NaCl (pH 8.0). Cells were lysed osmotically by 
addition of 3 ml 0.1 M NaPO (pH 8.0) without NaCl. 
Protease inhibitor cocktail (Thermo Pierce) was added, and 
the lysate was centrifuged at 22,000xg for one hour to pellet 
cell debris and membranes. The concentration of soluble 
cytoplasmic protein in the resulting extract was measured 
via Bradford assay against a 2 mg BSA standard (Thermo 
Pierce). Har assays (Welte and Deppenmeier, 2014, Supra) 
were modified for a 96-well plate format. Briefly, reactions 
were prepared with 170 ul 0.1 M NaPO (pH 8.0), 28 ul 
extract and 2 ul methyl viologen. The reaction was began 
with the addition of 30 ul CoM-CoB heterodisulfide, and the 
increase in oxidized methyl viologen was followed at 578 
nm in a Tecan Sunrise plate reader at 35° C. 
Example 2 
General Description of Strain Construction 
To generate the AhdraBC strains, the hdraBC sequence 
was mutated using site-directed mutagenesis and overlap 
ping PCR. Primers and DNA sequences in Table 2 were 
designed using Vector NTI software (Invitrogen). Genes, 
oligos, and multiple cloning sites were synthesized com 
mercially by IDT and Invitrogen. To overexpress hdraCB, 
the operon (MA3126-3128) was amplified from the M. 
acetivorans chromosome (strain NB34) using primers 














oNB72-oNB81 introduced five point mutations to remove 
five Ndel restriction sites from the hdraCB operon. The 
resulting fused PCR product contained BamHI restriction 
sites at the 5' and 3' ends, as well as an Ndel site preceding 
the start codon of the hdra gene. The PCR product was 
ligated into plasmid pNB708, creating pNB709, and verified 
by restriction digest and sequencing. The mutated hdraCB 
operon was amplified from pNB709 using oligos onB68 and 
oNB69, and ligated into plK027A at the Ndel and BamHI 
restriction sites to create plasmid pC1 (Table 1). The 
hdraBC operon is under control of the PmcrB(tetO1) (aka 
Ptet) promoter. The Ptet promoter is constitutive when 
transformed into strains lacking the tetR repressor gene, but 
can be controlled by addition of tetracycline in strains that 
express TetR repressor. M. acetivorans was transformed 
with pC1 as previously described (Buan and Metcalf, 2010, 
Mol. Microbiol. 75:843-53). Transformants were verified 
via PCR screen for wild type harABC, the AhdraBC operon 
deletion, and Ptet hdraBC (in pC1) using primers listed in 
Table 2. Various PCR techniques were employed to create 
methanophenazine mutant strains (listed in Table 1), includ 
ing overlap extension and site-directed mutagenesis. 
For all PCR reactions, Phusion Flash PCR Master Mix 
was used as a source of proofreading DNA polymerase 
(Thermo Scientific). DNA purification was carried out using 
Wizard kits from Promega (Madison, Wis.). DNA fragments 
were joined using T4 DNA Ligase (New England Biolabs) 
or GeneArt kits (Invitrogen). Restriction enzymes (AScI. 
BamHI, Ndel. Ncol, EcoRI, SphI, Xbal) were purchased 
from New England Biolabs (Ipswich, Mass.). All plasmids 
were sequenced by Eurofins Operon MWG (Huntsville, 
Ala.). 
After purification from E. coli, the plasmids were trans 
fected into M. acetivorans using liposome-mediated trans 
fection (using the DOTAP liposome transfection reagent 
from Roche), and the operon was recombined into the 
genome. Colonies then were selected for puromycin resis 
tance (from the puromycin acetyltransferase cassette 
included on the plC1 vector). Certain of the strains and their 
genotype are provided in Table 1. 
TABLE 1. 
Strains and Genotypes 
E. coli strains 
NB 
# Genotype Purpose Source 
3 F" proA+B+ lacla A(lacz)M15 5C. Flacl2. New 
ZZf::Tn10 (TetR)ffhuA2A(argF- Replication of England 
lacz)U169 phoA glnV44 pNEB193 Biolabs 
d80A(lacZ)M15 gyra96 recA1 derived plasmids. 
endA1 thi-1 hsdR17 
10 F- mcra A(mirr-hsdRMS-mcrBC) DH10B att::pAMG27. Guss 
p80laczAM15 AlacX74 recA1 Replication of oriV AM, 
arad139 A(ara-leu) 7697 gall J copy-control plasmids. et al. 
galK rpsL (StrR) endA1 nupG - High copy replication 2008 
att::Prha trfA33-254D is induced by addition 
of rhamnose. 
pNEB193 derivative plasmids 
NB Plasmid 
# Genotype Purpose l8le Source 
13 plJC ori, E. coli cloning pNEB193 New 
bla- England 
Biolabs 
47 plJC ori, 
bla--, 
Nicol 










Strains and Genotypes 
adds Ncol site to pNEB193 pNB708 
M. acetivorans Ndel pNB709 
hdra1C1B1 operon (with 
all internal Ndel sites 
removed) cloned into the 
BamHI site 
pK027A derivative plasmids 
Purpose 
Integration at pC31 
attP site 







of HodrABC protein 
in Meihanosarcina. 
Tetracycline-controlled 






Methanosarcina acetivorans C2A strains 
NB 
i Genotype Purpose 
34 Ahpt::pC31 int, attP Parental strain 
36 AhdraCBAAhpt::cpC31 AhdraBC mutant 
int, attP 
105 Ahpt::pC31 int, 
106 AhdraCB Ahpt::pC31 
overproduction 
Effect of constitutive 
of HoraBC. att::hdraBC 
int, att::pC1 Ahdra BC by plC1. 
AhdraBC att::hdraBC 
Complementation of 





























Construction of the NB105 Strain 
The hdraBC genes (MA3126-3128; see Galagan et al., 
2002, Genome Res., 12:532-42; see, also, GenBank Acces 
sion No. AE010299) were amplified from the M. acetivorans 
chromosome (strain NB34, propagated from M. acetivorans 
strain, WWM82, from Dr. Metcalf's Lab, University of 
Illinois, Urbana-Champaign on July 2010) chromosome 
using primers oNB68, onB69, onB72-81 (see Table 2). The 
listed oligos simultaneously amplify the hadr ABC operon 
and create mutations that remove internal Ndel restriction 
sites (the wild-type operon contains five) and results in a 
PCR product that has a BamHI restriction site after the stop 
codon on the 3' end of the operon. 
The mutated hdraBC operon then was cloned into the E. 
coli plasmid, pNB708, at the BamHI site. pNB708 was 
produced using oligos, onB60 and oNB61 (see Table 2), to 
amplify plasmid, pNEB 193 (purchased from New England 
Biolabs). The resulting PCR product was digested with 
Dpn1 and transformed into E. coli strain, NB3 (New Eng 
land Biolabs), to produce plasmid, pNB708, which has a 
new Ncol site in the plasmid. The E. coli strain carrying 
pNB708 was designated NB47. 
The resulting plasmid, pNB709, carried in E. coli strain, 
NB48, was used as a template in subsequent PCR reactions 
to amplify the mutated hdraBC operon with oligos, onB68 
and onB69 (see Table 2). The mutated hdraBC operon was 
cloned into pK027A at the Ndel and BamHI sites to 
produce plasmid pC1. p C1 contains a pC31 attP site, and, 
in the presence of (pC31 recombinase, is inserted into any 
DNA containing the pC31 attB site. p.JC1 also contains a 
mutated hdraBC operon driven by the PtetO1 promoter, 
which is transcribed constitutively in Methanosarcina spe 
cies unless the parent strain expresses a TetR repressor 
protein, in which case, HdrABC expression is rendered 
tetracycline-inducible by TetR binding to the tetO1 operator 
site on the promoter. pC1 was transformed into NB34 to 
create strain NB105, in which pC1 has recombined into the 
M. acetivorans (NB34) chromosome at the hpt locus. In 
cell-suspension assays with methanol, strain NB105 pro 
duced methane at a rate that was 35% faster than that of the 




68 M. acetivorans BamHI 
Ndle horABC BamHI fwc 
69 M. acetivorans BamHI 
Ndle horABC BamHI 
72 removes NdeI site 
73 removes NdeI site 
74 removes NdeI site 
75 removes NdeI site 
76 removes NdeI site 
77 removes NdeI site 
78 removes NdeI site 
79 removes NdeI site 
80 removes NdeI site 


































oNB: Purpose Sequence (5'-3') SEQ ID NO : 
122 horA: amplifies within TACTGGGGTTTCTGGGAGAC 19 
inside both parent and 
insert hdra. 
376 identify hdrABC deletion: ATGGTCTTGCTCTCAGCGATGA 2O 
amplifies 5' upstream of 
MA3128 
377 identify hdrABC deletion: AGGTGTTGGTATGAAAATCAGCAAGG 21 
amplifies 3" downstream 
of MA3126 
379 identify Ptet hdrABC insert ATCAGTGATAGAGATTTCATTGGGAATAGT 22 
Example 4 
Evaluation of Strains 
The growth kinetics of the strains indicated above in Table 
1 were used to evaluate the growth phenotypes of each strain 
on methanol, methanol--acetate, or acetate Substrates, using 
Method (1) described above (“BT+Spec20), and the results 
are shown in Table 3. 
TABLE 3 
25 
Culture Doubling Time for Adapted Cells (Hours 
Growth Substrate 
MeOH MeOH + Acetate Acetate 
Std p vs p vs Std p vs p vs Std p VS p VS 
Strain hours dev Parent AhdraBC hours dev Parent AhdraBC hours dev Parent AhdraBC 
Parent 8.5 O.17 1 OOOOO 9.4 O.28 1 OOO46 44.O 280 1 O.OOOO 
att::hdraBC 8.4 0.11 NS O.OOO1 9.7 0.16 NS NS 47.6 2.64 NS O.OOO3 
AhdraBC 9.1 0.14 O.OO12 OOO10 10.3 0.48 NS NS S8.0 3.05 O.OOO2 NS 
att::hdraBC 
AhdraBC 9.9 0.24 OOOOO 1 10.1 -0.2O O.OO46 1 61.8 2.94 OOOOO 1 
Cells were adapted to methanol for 25 generations. Data were collected from five biological replicates (N = 5). Significance p values determined 
by unpaired Student's t-test, 
NS: not significant, p > 0.01. 
The strains indicated above in Table 1 were used to 
evaluate the production of methane from methanol or acetate 
using Method (1) described above (methane production and 
biomass measurements), and the results are shown in Table 
4. 
TABLE 4 
Growth Yield and Methane Yield 
Biomass 
Strain g mol' Std dev p vs Parent 
Parent 7.295 0.7378 1 
att::hdraBC 6.977 O.6S6S NS 
AhdraBC att::hdraBC 7.02O 0.7550 NS 







Growth Yield and Methane Yield 
Methane 
Strain mmoles l' Std dev p vs Parent 
Parent 95.0 3.66 1 
att::hdraBC 95.7 1.77 NS 
AhdraBC att::hdraBC 95.9 2.62 NS 
AhdraBC 97.6 3.71 NS 
Cells were adapted to methanol for 25 generations. Data were collected from ten biological 
replicates (N = 10). Significance p values determined by unpaired Student's t-test, NS: not 
significant, p > 0.01. Theoretical methane yield: 93.75 mmoles 1-1. 
Example 5 
Evaluating the Substrate Specificity of HarABC 
As shown in Table 3, acetate resolves the phenotype 
produced by overexpression of HarABC. Since these results 
suggest that HarABC is specific for growth on methylo 
trophic substrates (with chemical formula of CH3-X, where 
X represents any element except carbon), experiments were 
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performed to determine if HarABC uses an electron donor 
produced in acetate-grown cells. To make this determina 
tion, the rates of methane production on acetate Substrates 
with or without methanol are measured, suggesting that 
HdrABC is lacking the appropriate electron donor in 
acetate-grown cells. 
Example 6 
Evaluating the Role of Electron Bifurcation 
As shown in FIG. 5, altering HarABC enzyme activity in 
the cells affects the rate of growth, the rate of methane 
production, and the amount of biomass that is produced. The 
amount of HarABC activity has a direct positive correlation 
with the rate of methane produced from methanol (R’—1.00). 
The rate of growth and methane rate have a second-order 
correlation (R=0.99). The rate of growth also is correlated 
to the rate of HarABC activity by a second-order relation 
ship (R=0.99). Finally, the amount of biomass has a direct 





As shown in FIG. 6, the effect of HarABC expression on 
Methanosarcina is to decrease the metabolic efficiency of 
the organism, i.e., more Substrate is channeled to methane 
production at the expense of biomass synthesis. Metabolic 
efficiency is defined by the equation: 
x 100 
kCH 
Where k is defined as the growth rate and k is defined as 
the rate of methane production. The level of HarABC 
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- Continued 
ccggacagga agctct tact gtttalaga.gc tigcatggtcg 
gaaa.ca.gc.ca C cagttacgt gtttgaccgg Cttgggg tag 
Cagt cctgct gtacaggaat aggcc act at accgatgtct 
gccattgcag ccc.ggaactt to cqtcgcc agaaagtgcg 
citctgttcaa cct gttatgc cataaacaag gacgcatgcg 
aaaaagttcaa ctic catctitc gggg.tc.cggg cgggaaaaag 
gaaaaggact coatgaac cc cagaaccaat atctato acg 
aaagttcgaaa agat.ccggga agagataaag titcgattitcC 
catcacgcct gcc act atta taaagttcaaa taccttgacg 
CCCC agctta tag acacgat agc.cgaagcc ticggggcat 
gatcgaac cc ticacctg.cgg aatgggcttt toccagotcc 
citcc aggtta ccaaaacaaa acttgacago citccagagag 
catgtgtgcc cqaact gcca tat coagtac gaccgct acc 
agtacgacat aac attgcc.c titcggggttg ggtgcacatg 
cct acaaagt atgcggitt to cagact cact ggagcagacic 
cittgaaaaga ccggaataat ataatgtcca gtttcaaagt 
ttacat cqgg agtgaagaggg 
Mac hors (mutated) 
LKAIESIPDR KLLLFKSCMV GOEYPGIETA TSYWFDRLGV 
FEGLTTAAIA, ARNFAWARKC GYPNITCLCS TCYAINKDAC 
GFDDLWYEKD SMNPRTNIYH AWEWLLSKWE KIREEIKFDF 
VIGNPENPOL IDTIAEACGA SPWRWYEDRT LTCGMGFSQL 
AGVELMIHVC PNCHIOYDRY OPVIEKEFGV EYDMVHMNIA 
SWPLEGFLEK. TGIIk 
It is to be understood that, while the methods and com 
positions of matter have been described herein in conjunc 
tion with a number of different aspects, the foregoing 























not limit the scope of the methods and compositions of 45 
matter. Other aspects, advantages, and modifications are 
within the scope of the following claims. 
Disclosed are methods and compositions that can be used 
for, can be used in conjunction with, can be used in prepa 
ration for, or are products of the disclosed methods and 
compositions. These and other materials are disclosed 
herein, and it is understood that combinations, Subsets, 
interactions, groups, etc. of these methods and compositions 
SEQUENCE LISTING 




SEO ID NO 1 
LENGTH: 4101 
TYPE: DNA 
ORGANISM: Methanosarcina acetivorans 
<4 OOs SEQUENCE: 1 
atgactgacg ggctgaacaa agctg.ccgta tittatctgcc actgcagogg gaat attt Co 













aag cacct ct 
gctaatgat c 
cgaaaaagag 
cct ct caatg 
ggaaggattt 
acct t t t t ta. 







are disclosed. That is, while specific reference to each 
various individual and collective combinations and permu 
tations of these compositions and methods may not be 
explicitly disclosed, each is specifically contemplated and 
described herein. For example, if a particular composition of 
matter or a particular method is disclosed and discussed and 
a number of compositions or methods are discussed, each 
and every combination and permutation of the compositions 
and the methods are specifically contemplated unless spe 
cifically indicated to the contrary. Likewise, any Subset or 














































































































































































































































































































































































































































































































































































































SEQ ID NO 3 
LENGTH: 
TYPE : 






































































































































































































































































































































































<210s, SEQ ID NO 4 
&211s LENGTH: 
212. TYPE : 
<213> ORGANISM: Methanosarcina acetivorans 
PRT 
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41 
- Continued 
Catgtgtgcc caactgc.ca tat coagtac gaccgct acc agc.ccgttat caaaaagag 3900 
titcggggttg agtacgacat ggtgcacatgaac attgc.cc agttcgtagc cct ct caatg 396 O 
ggagcagacic cct acaaagt atgcggtttc Cagactic act C cqtgcctct ggaaggattt 4 O2O 
cittgaaaaga ccggaataat ataatgtcca gtttcaaagt agaactggct accttttitta 4 O8O 
ttacat cqgg agtgaagaggg 41 O1 
<210s, SEQ ID NO 6 
&211s LENGTH: 314 
212. TYPE: PRT 
<213> ORGANISM: Methanosarcina acetivorans 
22 Os. FEATURE: 
223 OTHER INFORMATION: multant 
<4 OOs, SEQUENCE: 6 
Lieu Lys Ala Ile Glu Ser Ile Pro Asp Arg Llys Lieu Lleu Lieu. Phe Lys 
1. 5 1O 15 
Ser Cys Met Val Gly Glin Glu Tyr Pro Gly Ile Glu Thir Ala Thir Ser 
2O 25 3O 
Tyr Val Phe Asp Arg Lieu. Gly Val Asp Tyr Cys Ile Asn Asp Glu Glin 
35 4 O 45 
Ser Cys Cys Thr Gly Ile Gly His Tyr Thr Asp Val Phe Glu Gly Lieu. 
SO 55 6 O 
Thir Thr Ala Ala Ile Ala Ala Arg Asn. Phe Ala Val Ala Arg Lys Cys 
65 70 7s 8O 
Gly Tyr Pro Asn Ile Thr Cys Lieu. Cys Ser Thr Cys Tyr Ala Ile Asn 
85 90 95 
Lys Asp Ala Cys Glu Lieu. Lieu. Asn. Thir Asn Asp Gly Val Arg Glu Lys 
1OO 105 11 O 
Val Asn. Ser Ile Phe Arg Glu Lys Gly Phe Asp Asp Lieu Val Tyr Glu 
115 12 O 125 
Lys Asp Ser Met Asn Pro Arg Thr Asn. Ile Tyr His Ala Val Glu Val 
13 O 135 14 O 
Lieu. Lieu. Ser Llys Val Glu Lys Ile Arg Glu Glu Ile Llys Phe Asp Phe 
145 150 155 160 
Pro Gly Val Lys Ala Ala Ser His His Ala Cys His Tyr Tyr Llys Val 
1.65 17O 17s 
Llys Tyr Lieu. Asp Val Ile Gly Asn Pro Glu Asn. Pro Gln Lieu. Ile Asp 
18O 185 19 O 
Thir Ile Ala Glu Ala Cys Gly Ala Ser Pro Val Arg Trp Tyr Glu Asp 
195 2OO 2O5 
Arg Thr Lieu. Thr Cys Gly Met Gly Phe Ser Gln Lieu. His Lieu. Asn Lys 
21 O 215 22O 
Ser Thir Ser Lieu. Glin Val Thir Lys Thir Lys Lieu. Asp Ser Lieu. Glin Arg 
225 23 O 235 24 O 
Ala Gly Val Glu Lieu Met Ile His Val Cys Pro Asn Cys His Ile Glin 
245 250 255 
Tyr Asp Arg Tyr Glin Pro Val Ile Glu Lys Glu Phe Gly Val Glu Tyr 
26 O 265 27 O 
Asp Met Val His Met Asn Ile Ala Glin Phe Val Ala Leu Ser Met Gly 
27s 28O 285 
Ala Asp Pro Tyr Lys Val Cys Gly Phe Glin Thr His Ser Val Pro Leu 
29 O 295 3 OO 
Glu Gly Phe Leu Glu Lys Thr Gly Ile Ile 
3. OS 310 
US 9,598,678 B2 
43 
- Continued 
<210s, SEQ ID NO 7 
&211s LENGTH: 33 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OO > SEQUENCE: 7 
ggat.cccata tactgacgg gctgaacaaa gCt 
<210s, SEQ ID NO 8 
&211s LENGTH: 46 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 8 
ggat.ccc.cct citt cactic cc gatgtaataa aaaaggtagc cagttc 
<210s, SEQ ID NO 9 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 9 
gagaaattgc ctittttgtcc atgtgtc.cgc agttgaactic gtc 
<210 SEQ ID NO 10 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 10 
gacgagttca actg.cggaca catggacalaa aaggcaattt Ctc 
<210s, SEQ ID NO 11 
&211s LENGTH: 42 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 11 
c ctitttgttgttcggaacgta togcttttittgaaatagatcc gg 
<210s, SEQ ID NO 12 
&211s LENGTH: 42 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 12 
ccggat citat ttcaaaaaag catacgttcc gaacacaaaa go 
<210s, SEQ ID NO 13 
&211s LENGTH: 39 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
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- Continued 
<4 OOs, SEQUENCE: 13 
ggcatcatct ttacataggg tat catctta t catctotc 
<210s, SEQ ID NO 14 
&211s LENGTH: 39 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 14 
gagagatgat aagatgatac Cctatgtaaa gatgatgcc 
<210s, SEQ ID NO 15 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 15 
gggitat cqta titcgtttaca tagggcatca totttacata togg 
<210s, SEQ ID NO 16 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 16 
c catatgtaa agatgatgcc ctatotaaac gaatacgata ccc 
<210s, SEQ ID NO 17 
&211s LENGTH: 42 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 17 
gatatggcag titcgggcaca ttggat cat tagct coaca CC 
<210s, SEQ ID NO 18 
&211s LENGTH: 42 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 18 
ggtgtggagc taatgatcca catgtgc.ccg aactgccata t c 
<210s, SEQ ID NO 19 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
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- Continued 
SEQ ID NO 2 O 
LENGTH: 22 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 2O 
atggtcttgc tict cagcgat ga 
SEQ ID NO 21 
LENGTH: 26 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 21 
aggtgttggt atgaaaatca gcaagg 
SEQ ID NO 22 
LENGTH: 30 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 22 
atcagtgata gagattt cat tgaatagt 
What is claimed is: 
1. A mutant heterodisulfide reductase-like protein subunit 
B (HdrB) polypeptide, wherein the mutant HarB polypep 
tide comprises an amino acid sequence with at least 95% 
sequence identity to the amino acid sequence of SEQ ID 
NO: 3, wherein methionine at the amino acid corresponding 
to position 249 of SEQ ID NO: 3 is substituted with valine 
in the mutant HarB polypeptide, and wherein when the 
mutant HarB polypeptide is combined with a heterodisulfide 
reductase-like protein subunit A (HdrA) polypeptide and a 
heterodisulfide reductase-like protein subunit C (HdrC) 
polypeptide forms an HarABC enzyme that has heterodis 
ulfide reductase activity. 
2. The mutant HarB polypeptide of claim 1, wherein the 
mutant HarB polypeptide comprises the amino acid 
sequence of SEQ ID NO:6. 
3. A nucleic acid molecule comprising a polynucleotide 
encoding the mutant HarB polypeptide of claim 1. 
4. The nucleic acid molecule of claim 3, wherein the 
polynucleotide comprises the nucleotide sequence of SEQ 
ID NO: 5. 
5. The nucleic acid molecule of claim 3, wherein the 
mutant HarB polypeptide comprises the amino acid 
sequence of SEQ ID NO: 6. 
6. The nucleic acid molecule of claim 1, further compris 









like protein subunit A (HdrA) polypeptide and a polynucle 
otide encoding a heterodisulfide reductase-like protein 
subunit C (HdrC) polypeptide. 
7. A microorganism comprising the nucleic acid molecule 
of claim 3. 
8. The microorganism of claim 7, wherein the microor 
ganism is a methanogen. 
9. The microorganism of claim 8, wherein the microor 
ganism is Methanosarcina acetivorans. 
10. The microorganism of claim 7, wherein the nucleic 
acid molecule is expressed in the microorganism via an 
expression vector. 
11. A microorganism comprising the nucleic acid mol 
ecule of claim 6. 
12. The microorganism of claim 11, wherein the micro 
organism is a methanogen. 
13. The microorganism of claim 12, wherein the micro 
organism is Methanosarcina acetivorans. 
14. The microorganism of claim 11, wherein the nucleic 
acid molecule is expressed in the microorganism via an 
expression vector. 
15. A method of producing methane, comprising culturing 
the microorganism of claim 11 under appropriate conditions 
to express the HarA polypeptide, the mutant HarB polypep 
tide, and the HarC polypeptide and produce methane. 
k k k k k 
